{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-08T04:22:34.509409+00:00","company":{"ticker":"RBOT","cik":1812173,"company_name":"Vicarious Surgical Inc."},"pagination":{"limit":100,"returned":20,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"exchange_compliance_notice","fact_key":"201d6fc96307bc0598e7bfef97be683d468a2407","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2026-03-04T23:59:59+00:00","payload":{"company_response":"evaluating appeal","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nyse","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2026-03-03","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":"Section 802.01B of the NYSE Listed Company Manual","reported_value":null,"rule_numbers":["802.01B"],"rules_cited_in_text":true},"claim":"Vicarious Surgical Inc. received a nyse delisting notice notice regarding market value (rules 802.01B).","evidence_excerpt":"March 3, 2026, the New York Stock Exchange (the “NYSE”)\nnotified Vicarious Surgical Inc. (the “Company”) that the NYSE had determined to (A) immediately suspend trading in the Company’s\ncommon stock, par value $0.0001 per share (the “Common Stock”), due to a determination that the Company had fallen below the\nNYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive\n30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings\nto delist the Commo","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-023404","anchor_url":"https://secwatch.observer/filing/0001213900-26-023404#claim-201d6fc96307bc0598e7bfef97be683d468a2407","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390026023404/0001213900-26-023404-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"5ac5563b2bc5d7d7e2020bf5a8971b122472f637","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-12-16T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-10-10","deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nyse","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-12-16","notice_type":"noncompliance_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["802.01B"],"rules_cited_in_text":true},"claim":"Vicarious Surgical Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).","evidence_excerpt":"YSE’s determination. Trading in the Company’s Common Stock will\nbe unaffected and will continue on the NYSE under the symbol “RBOT”. Continued trading of the Company’s Common Stock\nremains subject to the Company’s ability to regain compliance with the continued listing standard set forth in Section 802.01B of\nthe NYSE’s Listed Company Manual prior to the expiration of the previously announced eighteen-month cure period on October 10, 2026,\nand continued compliance with the NYSE’s other continued listing requirements.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001213900-25-122267","anchor_url":"https://secwatch.observer/filing/0001213900-25-122267#claim-5ac5563b2bc5d7d7e2020bf5a8971b122472f637","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"5f563bb55e46331bcd71ba559cb5e97e6385b73a","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-12-16T23:59:59+00:00","payload":{"company_response":"The Company does not intend to appeal","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"other","delisting_effective_date":null,"exchange":"nyse","hearing_date":null,"immediate_listing_effect":true,"minimum_requirement":null,"notice_date":"2025-12-15","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["802.01D"],"rules_cited_in_text":true},"claim":"Vicarious Surgical Inc. received a nyse delisting notice notice regarding other (rules 802.01D).","evidence_excerpt":"December 15, 2025, the NYSE notified the Company\nthat the NYSE has determined to (a) commence proceedings to delist the Company’s warrants, with thirty warrants exercisable for\none share of Common Stock, at an exercise price of $345.00 per share, and listed to trade on the NYSE under the symbol “RBOT.WS”\n(the “Public Warrants”) and (b) immediately suspend trading in the Public Warrants due to “abnormally low” trading\nprice levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Common Stock w","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-122267","anchor_url":"https://secwatch.observer/filing/0001213900-25-122267#claim-5f563bb55e46331bcd71ba559cb5e97e6385b73a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025122267/0001213900-25-122267-index.htm"},{"fact_type":"equity_issuance","fact_key":"5a95f871e40564c95d7394ae71878aff5c815422","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-10-08T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"aggregate gross proceeds from the Offerings of approximately $5.9 million","effective_date":"2025-10-07","item_codes_triggered":["3.02"],"purchaser":"institutional investor","security_type":"warrant","shares_text":"Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 1,150,000 shares of Common Stock"},"claim":"Vicarious Surgical Inc. issued Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 1,150,000 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.","evidence_excerpt":"Form 8-K as the “Offerings.” The Company expects\nthe Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9\nmillion, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent\nfees and other offering expenses payable by the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-097471","anchor_url":"https://secwatch.observer/filing/0001213900-25-097471#claim-5a95f871e40564c95d7394ae71878aff5c815422","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025097471/0001213900-25-097471-index.htm"},{"fact_type":"equity_issuance","fact_key":"7f6e214602a37075054ad740aec7cb1dbea10bdf","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-10-08T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"aggregate gross proceeds from the Offerings of approximately $5.9 million","effective_date":"2025-10-07","item_codes_triggered":["3.02"],"purchaser":"institutional investor","security_type":"warrant","shares_text":"Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 1,150,000 shares of Common Stock"},"claim":"Vicarious Surgical Inc. issued Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 1,150,000 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.","evidence_excerpt":"Form 8-K as the “Offerings.” The Company expects\nthe Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9\nmillion, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent\nfees and other offering expenses payable by the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-097471","anchor_url":"https://secwatch.observer/filing/0001213900-25-097471#claim-7f6e214602a37075054ad740aec7cb1dbea10bdf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025097471/0001213900-25-097471-index.htm"},{"fact_type":"equity_issuance","fact_key":"34b4af38c077a66ea78e1e04475b0362fa47518b","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-10-08T23:59:59+00:00","payload":{"action":"registered_direct","consideration_text":"aggregate gross proceeds from the Offerings of approximately $5.9 million","effective_date":"2025-10-07","item_codes_triggered":["3.02"],"purchaser":"institutional investor","security_type":"warrant","shares_text":"pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 561,700 shares of Common Stock"},"claim":"Vicarious Surgical Inc. issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 561,700 shares of Common Stock of warrant to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.","evidence_excerpt":"Form 8-K as the “Offerings.” The Company expects\nthe Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9\nmillion, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent\nfees and other offering expenses payable by the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-097471","anchor_url":"https://secwatch.observer/filing/0001213900-25-097471#claim-34b4af38c077a66ea78e1e04475b0362fa47518b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025097471/0001213900-25-097471-index.htm"},{"fact_type":"equity_issuance","fact_key":"a814d614b54be1a5226b6c2826d26aca0db8988d","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-10-08T23:59:59+00:00","payload":{"action":"registered_direct","consideration_text":"aggregate gross proceeds from the Offerings of approximately $5.9 million","effective_date":"2025-10-07","item_codes_triggered":["3.02"],"purchaser":"institutional investor","security_type":"common_stock","shares_text":"588,300 shares"},"claim":"Vicarious Surgical Inc. issued 588,300 shares of common stock to institutional investor for aggregate gross proceeds from the Offerings of approximately $5.9 million.","evidence_excerpt":"Form 8-K as the “Offerings.” The Company expects\nthe Offerings to close on or about October 9, 2025 and to receive aggregate gross proceeds from the Offerings of approximately $5.9\nmillion, excluding any proceeds that may be received upon the exercise of the Common Warrants and before deducting placement agent\nfees and other offering expenses payable by the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-097471","anchor_url":"https://secwatch.observer/filing/0001213900-25-097471#claim-a814d614b54be1a5226b6c2826d26aca0db8988d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025097471/0001213900-25-097471-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"d401027296f2d682f573b35b388cdcc4a2d74370","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-07-11T23:59:59+00:00","payload":{"company_response":"submitted Compliance Plan, accepted on July 8, 2025","compliance_status":"extension_granted","cure_deadline":"2026-10-10","deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nyse","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-04-10","notice_type":"noncompliance_notice","plan_due_date":"2025-04-10","raw_rule_text":"Section 802.01B of the NYSE's Listed Company Manual (the \"Minimum Market Capitalization Standard\")","reported_value":"average global market capitalization less than $50 million; stockholders' equity less than $50 million","rule_numbers":["802.01B"],"rules_cited_in_text":true},"claim":"Vicarious Surgical Inc. received a nyse noncompliance notice notice regarding market value (rules 802.01B).","evidence_excerpt":"April 10, 2025, Vicarious\nSurgical Inc. (the “Company”) received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”)\nindicating the Company was no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the\nNYSE’s Listed Company Manual (the “Minimum Market Capitalization Standard”) due to the fact that the Company’s\naverage global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’\nequity was less than $50 million. In accordance with applicable NYSE p","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-063296","anchor_url":"https://secwatch.observer/filing/0001213900-25-063296#claim-d401027296f2d682f573b35b388cdcc4a2d74370","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025063296/0001213900-25-063296-index.htm"},{"fact_type":"auditor_change","fact_key":"9cbfc233f7e268c1596b5b40544c44085929c9b3","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-07-11T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Cherry Bekaert LLP","disagreement_text":null,"effective_date":"2025-07-07","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Vicarious Surgical Inc. engaged Cherry Bekaert LLP as its auditor.","evidence_excerpt":"On July 7, 2025, in connection with the Company’s dismissal of Deloitte, the Audit Committee approved the engagement of Cherry Bekaert as its new independent registered public accounting firm","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-063296","anchor_url":"https://secwatch.observer/filing/0001213900-25-063296#claim-9cbfc233f7e268c1596b5b40544c44085929c9b3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025063296/0001213900-25-063296-index.htm"},{"fact_type":"auditor_change","fact_key":"1f1525a3db440d9caf7d529093f0b53595825770","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-07-11T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Deloitte & Touche LLP","disagreement_text":null,"effective_date":"2025-07-07","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Cherry Bekaert LLP"},"claim":"Vicarious Surgical Inc. dismissed Deloitte & Touche LLP as its auditor.","evidence_excerpt":"On July 7, 2025, the Company dismissed Deloitte & Touche LLP (\"Deloitte\") as the Company’s independent registered public accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-063296","anchor_url":"https://secwatch.observer/filing/0001213900-25-063296#claim-1f1525a3db440d9caf7d529093f0b53595825770","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025063296/0001213900-25-063296-index.htm"},{"fact_type":"executive_change","fact_key":"70260d79fd","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-03-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-25","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Randy Clark was appointed as Director at Vicarious Surgical Inc..","evidence_excerpt":"the Company’s Board of Directors (the “Board”) has appointed Mr. Clark to the Board, effective as of April 25, 2025, pending customary conflict checks.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001013762-25-001611","anchor_url":"https://secwatch.observer/filing/0001013762-25-001611#claim-70260d79fd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000101376225001611/0001013762-25-001611-index.htm"},{"fact_type":"executive_change","fact_key":"8e85479c5a","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-03-24T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-25","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Randy Clark resigned as President at Vicarious Surgical Inc..","evidence_excerpt":"On March 18, 2025, Randy Clark resigned as President of Vicarious Surgical Inc. (the “Company”), effective as of April 25, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001013762-25-001611","anchor_url":"https://secwatch.observer/filing/0001013762-25-001611#claim-8e85479c5a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000101376225001611/0001013762-25-001611-index.htm"},{"fact_type":"executive_change","fact_key":"462e1c29ea","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-03-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-01","interim":false,"role":"Chief Financial Officer and Treasurer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Sarah Romano was appointed as Chief Financial Officer and Treasurer at Vicarious Surgical Inc..","evidence_excerpt":"On March 13, 2025, Vicarious Surgical Inc. (the “Company”) announced that Sarah Romano was appointed by the Board of Directors of the Company (the “Board”) as Chief Financial Officer and Treasurer of the Company, effective April 1, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-023441","anchor_url":"https://secwatch.observer/filing/0001213900-25-023441#claim-462e1c29ea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025023441/0001213900-25-023441-index.htm"},{"fact_type":"executive_change","fact_key":"2f69523a1b","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-02-18T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2025-04-01","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"John Mazzola departed as Chief Operating Officer at Vicarious Surgical Inc..","evidence_excerpt":"On February 12, 2025, John Mazzola notified the Company that he intends to retire from his position as Chief Operating Officer of Vicarious Surgical Inc. (the “Company”), effective April 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-014890","anchor_url":"https://secwatch.observer/filing/0001213900-25-014890#claim-2f69523a1b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025014890/0001213900-25-014890-index.htm"},{"fact_type":"executive_change","fact_key":"76724b75c3","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2025-01-21T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2025-01-02","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"William Kelly departed as Chief Financial Officer at Vicarious Surgical Inc..","evidence_excerpt":"On January 17, 2025, Vicarious Surgical Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with William Kelly in connection with Mr. Kelly’s previously disclosed departure from his role as Chief Financial Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-005036","anchor_url":"https://secwatch.observer/filing/0001213900-25-005036#claim-76724b75c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025005036/0001213900-25-005036-index.htm"},{"fact_type":"earnings_release","fact_key":"2f9b52f39e2c76940f133365ed4eb9473f78cdd3","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2024-04-29T23:59:59+00:00","payload":{"eps_text":"$0.10","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"GAAP net loss for the first quarter was $17.0 million, equating to a net loss per share of $0.10","period_text":"the quarter ended March 31, 2024","report_date":"2024-04-29","result_type":"reported_results","revenue_text":null},"claim":"Vicarious Surgical Inc. reported the quarter ended March 31, 2024 results: net income GAAP net loss for the first quarter was $17.0 million, equating to a net loss per share of $0.10, EPS $0.10. Guidance reaffirmed.","evidence_excerpt":"Vicarious Surgical Reports First Quarter 2024 Financial Results","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001213900-24-037162","anchor_url":"https://secwatch.observer/filing/0001213900-24-037162#claim-2f9b52f39e2c76940f133365ed4eb9473f78cdd3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390024037162/0001213900-24-037162-index.htm"},{"fact_type":"earnings_release","fact_key":"2b6d2e49040d3c58d529e2bed0d873f579d16c56","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2024-03-04T23:59:59+00:00","payload":{"eps_text":"GAAP net loss for the fourth quarter was $13.1 million, equating to a net loss per share of $0.06, as compared to a GAAP","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"GAAP net loss for the fourth quarter was $13.1 million, equating to a net loss per share of $0.06, as compared to a GAAP","period_text":"fourth quarter and full year ended December 31, 2023","report_date":"2024-03-04","result_type":"reported_results","revenue_text":null},"claim":"Vicarious Surgical Inc. reported fourth quarter and full year ended December 31, 2023 results: net income GAAP net loss for the fourth quarter was $13.1 million, equating to a net loss per share of $0.06, as compared to a GAAP, EPS GAAP net loss for the fourth quarter was $13.1 million, equating to a net loss per share of $0.06, as compared to a GAAP. Guidance reaffirmed.","evidence_excerpt":"On March 4, 2024, Vicarious Surgical Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023 and providing a business update.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-019553","anchor_url":"https://secwatch.observer/filing/0001213900-24-019553#claim-2b6d2e49040d3c58d529e2bed0d873f579d16c56","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390024019553/0001213900-24-019553-index.htm"},{"fact_type":"executive_change","fact_key":"84d382a410","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2024-03-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-02-29","interim":false,"role":"Executive Chairman","role_category":"chair","successor_name":null,"successor_named":false},"claim":"David Styka resigned as Executive Chairman at Vicarious Surgical Inc..","evidence_excerpt":"On February 27, 2024, David Styka notified the Board of Directors (the “Board”) of Vicarious Surgical Inc. (the “Company”) of his intent to resign as executive chairman and member of the Board, effective February 29, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-019546","anchor_url":"https://secwatch.observer/filing/0001213900-24-019546#claim-84d382a410","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390024019546/0001213900-24-019546-index.htm"},{"fact_type":"executive_change","fact_key":"44756d92ff","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2024-01-29T23:59:59+00:00","payload":{"action":"stepped down","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-01-29","interim":false,"role":"President","role_category":"president","successor_name":"Randy Clark","successor_named":true},"claim":"Adam Sachs changed role as President at Vicarious Surgical Inc..","evidence_excerpt":"In connection with the appointment of Mr. Clark, Adam Sachs stepped down from his role as President.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-007204","anchor_url":"https://secwatch.observer/filing/0001213900-24-007204#claim-44756d92ff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390024007204/0001213900-24-007204-index.htm"},{"fact_type":"executive_change","fact_key":"374506484a","cik":1812173,"ticker":"RBOT","company_name":"Vicarious Surgical Inc.","filed_at":"2024-01-29T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-29","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Randy Clark was appointed as President at Vicarious Surgical Inc..","evidence_excerpt":"On January 29, 2024, Vicarious Surgical Inc. (the “Company”) announced the appointment of Randy Clark as the President of the Company, effective as of the same day","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-007204","anchor_url":"https://secwatch.observer/filing/0001213900-24-007204#claim-374506484a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1812173/000121390024007204/0001213900-24-007204-index.htm"}]}